Norges Bank’s Summit Therapeutics SMMT Stock Holding History

Norges Bank’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.1M	Buy	+1,382,519	New	+$24.5M	﹤0.01%	1219
2026 Q1	–	Sell	-1,373,943	Closed	-$24M	–	1185
2025 Q4	$24M	Buy	+1,373,943	New	+$25.8M	﹤0.01%	1202
2025 Q3	–	Sell	-1,389,862	Closed	-$29.6M	–	1319
2025 Q2	$29.6M	Buy	1,389,862 +371,888	+37%	+$8.48M	﹤0.01%	1124
2025 Q1	$19.6M	Buy	1,017,974 +917,974	+918%	+$18.4M	﹤0.01%	1204
2024 Q4	$1.78M	Buy	+100,000	New	+$1.94M	﹤0.01%	1699

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Norges Bank's SMMT Position: Q2 2026 in Review

Norges Bank opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 1,382,519 shares worth $20.1M. The stake represents ﹤0.01% of the portfolio and ranks #1219 among its holdings. This is a return to the name: Norges Bank previously reported a position in SMMT as recently as Q4 2025.

Norges Bank first reported a position in SMMT in Q4 2024 and has held it in 5 quarters since. The position peaked at $29.6M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Norges Bank held 1,382,519 shares of Summit Therapeutics worth $20.1M as of Q2 2026.
Summit Therapeutics was a new Norges Bank position in Q2 2026.
Summit Therapeutics made up ﹤0.01% of Norges Bank's portfolio in Q2 2026, its #1219 holding.
Norges Bank first reported a position in Summit Therapeutics in Q4 2024 and has held it in 5 quarters since.
Norges Bank's Summit Therapeutics position peaked at $29.6M in Q2 2025.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Norges Bank's 13F filing for Q2 2026, filed 12 Aug 2026.